Cargando…
A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study
Purpose. To assess the safety profile of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (nAMD) in routine clinical practice. Methods. This 2-year, multicentre, observational study was conducted to capture real-world early practice and outcomes across Europe, shortly...
Autores principales: | Pagliarini, Sergio, Beatty, Stephen, Lipkova, Blandina, Perez-Salvador Garcia, Eduardo, Reynders, Stefaan, Gekkieva, Margarita, Si Bouazza, Abdelkader, Pilz, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020221/ https://www.ncbi.nlm.nih.gov/pubmed/24868458 http://dx.doi.org/10.1155/2014/857148 |
Ejemplares similares
-
VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION
por: Ceklic, Lala, et al.
Publicado: (2017) -
Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment
por: Ziemssen, Focke, et al.
Publicado: (2017) -
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
por: Prünte, Christian, et al.
Publicado: (2016) -
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
RANIBIZUMAB 0.5 MG TREATMENT IN ADOLESCENTS WITH CHOROIDAL NEOVASCULARIZATION: SUBGROUP ANALYSIS DATA FROM THE MINERVA STUDY
por: Hykin, Philip G., et al.
Publicado: (2021)